Nine Point Two Capital LLC Immunovant, Inc. Transaction History

Nine Point Two Capital LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $189,083 - $316,072	-55,942 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $98,103 - $170,032	19,388 Added 53.04%	55,942 $308,000
Q4 2021 Feb 11, 2022	BUY	$7.33 - $9.32 $193,409 - $245,917	26,386 Added 259.5%	36,554 $311,000
Q3 2021 Nov 10, 2021	BUY	$7.01 - $11.37 $71,277 - $115,610	10,168 New	10,168 $88,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Nine Point Two Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Nine Point Two Capital LLC with notifications on news.